Shots:
- Bio-Thera Solutions has collaborated with Tabuk Pharmaceuticals to commercialize BAT2206, biosimilar of Stelara (Ustekinumab) in Saudi Arabia
- The alliance will utilize Tabuk’s local footprint, sales & marketing abilities, with Tabuk handling marketing, registration, manufacturing & promotion of BAT2206. Bio-Thera will manage development & supply from its Guangzhou manufacturing facilities
- BAT2206, a proposed biosimilar to Janssen’s Stelara, is a human mAb that targets IL-12 & IL-23 by inhibiting p40 binding to IL-12Rβ1 on immune cells. Bio-Thera has filed for regulatory approval with the US FDA, EMA & NMPA
Ref: Bio-Thera Solutions and Tabuk Pharmaceuticals | Image: Bio-Thera Solutions and Tabuk Pharmaceuticals | Press Release
Related News:- Dong-A ST Receives EC Approval for Imuldosa (Biosimilar, Stelara)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
